ArticleJournal of the American Geriatrics Society2018
Serum Cholesterol and Incident Alzheimer's Disease: Findings from the Adult Changes in Thought Study.
Article in Journal of the American Geriatrics Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The influence of circulating cholesterol and its components in middle-aged adults on cognitive function at mid- and later-life; a systematic review.Frontiers in aging · 2025Pooled it
- Lipid levels and the risk of dementia: A dose-response meta-analysis of prospective cohort studies.Annals of clinical and translational neurology · 2022Pooled it
- Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study.Cardiovascular diabetology · 2025 · on this mapObservational
- A cross sectional study of the diabetes mediated GGT to HDL ratio and cognitive function in older adults.Scientific reports · 2025Article
- Dyslipidemia and cerebral atrophy among health check-up individuals: A cross-sectional study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Triglycerides, high-density lipoprotein and cognitive function in middle-aged and older adults: a cross-sectional analysis.Biogerontology · 2025Article
- U-shaped relationship between non-high-density lipoprotein cholesterol and cognitive impairment in Chinese middle-aged and elderly: a cross-sectional study.BMC public health · 2024Article
- Deciphering the effect of phytosterols on Alzheimer's disease and Parkinson's disease: the mediating role of lipid profiles.Alzheimer's research & therapy · 2024Article
- Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia.Molecular neurodegeneration · 2023Review
- Midlife lipid and glucose levels are associated with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Effect of a Vegan Diet on Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Low Values for Blood Pressure, BMI, and Non-HDL Cholesterol and the Risk of Late-Life Dementia.Neurology · 2022Observational
- Vascular Cognitive Impairment and Dementia.Continuum (Minneapolis, Minn.) · 2022Review
- The Role of High-Density Lipoprotein in Lowering Risk of Dementia in the Elderly: A Review.Cureus · 2022Review
- Article
- High-Fat and Resveratrol Supplemented Diets Modulate Adenosine Receptors in the Cerebral Cortex of C57BL/6J and SAMP8 Mice.Nutrients · 2021Article
- Low Cholesterol Level Linked to Reduced Semantic Fluency Performance and Reduced Gray Matter Volume in the Medial Temporal Lobe.Frontiers in aging neuroscience · 2020Article
- HDL from an Alzheimer's disease perspective.Current opinion in lipidology · 2019Review
- Reply to: Comment on: Serum Cholesterol and Incident Alzheimer's Disease: Findings From the Adult Changes in Thought Study.Journal of the American Geriatrics Society · 2019Article
- ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.Alzheimer's research & therapy · 2019Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate associations between high-density lipoprotein cholesterol (HDL) and non-HDL-C levels at specific ages and subsequent Alzheimer's disease (AD) risk.
designProspective population-based cohort study.
settingAdult Changes in Thought (ACT) Study.
participantsIndividuals aged 65 and older with no dementia at ACT Study entry. We identified separate, partially overlapping subcohorts of ACT participants who were eligible for each age band-specific analysis (50-59, n = 1,088; 60-69, n = 2,852; 70-79, n = 2,344; 80-89, n = 537). MEASUREMENTS: Exposure consisted of clinical measures of total cholesterol (TC) and HDL-C from laboratory data during a given age band. Outcomes of incident AD were assessed post-age band using standard research diagnostic criteria. Statistical analyses used adjusted Cox proportional hazards regression models for each exposure and outcome pair within an age band. Cholesterol exposures were modeled using cubic splines.
resultsFor non-HDL-C, we found a statistically significant association with AD risk in the 60 to 69 (omnibus p = .005) and 70 to 79 (omnibus p = .04) age bands, suggesting a potential U-shaped relationship (greater risk at low and high levels). For example, in people aged 60 to 69, those with an average non-HDL-C level of 120 mg/DL had a 29% greater AD hazard (hazard ratio (HR)=1.29, 95% confidence interval (CI)=1.04-1.61) than those with an average non-HDL-C level of 160 mg/dL, whereas those with an average non-HDL-C level of 210 mg/dL had a 16% greater hazard (HR=1.16, 95% CI=1.01-1.33). We did not find a statistically significant association between HDL-C and AD risk.
conclusionPeople with low (120 mg/dL) and high (210 mg/dL) non-HDL-C levels during their 60s and 70s had modestly higher risk of AD than those with intermediate (160 mg/dL) levels. The extreme age bands (50s and 80s) had small sample sizes. J Am Geriatr Soc 66:2344-2352, 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.